research Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy
Immunochemotherapy successfully treated neutropenia in a patient with Waldenström's macroglobulinemia.
Search
for
Sort by
Research
120-150 / 1000+ resultsresearch Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
The drug combination was safe and showed promise in treating advanced tumors.
research Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma
The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
research Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research Chemotherapy-induced toxicity—a secondary effect caused by released DNA?
Chemotherapy toxicity might be reduced by using DNA neutralizing agents.
research Immune Cells in Cutaneous Wound Healing: A Review of Functional Data from Animal Models
Different immune cells like platelets, mast cells, neutrophils, macrophages, T cells, B cells, and innate lymphoid cells all play roles in skin wound healing, but more research is needed due to inconsistent results and the complex nature of the immune response.
research Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
research Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
research Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Standardizing the 60-Second Hair Count
Men typically shed about 10 hairs in 60 seconds, and this amount doesn't increase with age.
research Tracion alopecia simulating lichen planopilaris
A woman's hair loss looked like a different condition due to her hairstyle, and treatment stopped further hair loss but didn't regrow hair.
research Animal models for the study of fetal tissue repair
Understanding how fetal wounds heal could help improve healing in adults.
research The effectiveness of fermented wheat germ extract as an adjunct therapy in the treatment of cancer: A systematic review
Avemar may help in cancer treatment, but its effectiveness isn't proven yet.
research An Underrecognized Adverse Effect of Azithromycin
Azithromycin can rarely cause a severe drop in white blood cells.
research Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Atypical folliculitis caused by Malassezia spp. in immunosuppressed patients
Some immunosuppressed patients can get unusual skin infections from Malassezia, which can be treated with antifungal medication.
research Oral Signs of Hematologic Disease
The conclusion is that different blood diseases cause specific oral symptoms and require varied treatments to manage these symptoms and improve patient health.
research Compliance To Medications In Rheumatology Clinic: The Patient Recall As An Indicator
Many patients in the rheumatology clinic adjusted or stopped their medications due to side effects.
research Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.
research Treatment of invasive aspergillosis with itraconazole
Itraconazole is potentially effective for treating invasive aspergillosis, but more research is needed.
research Role of liposomal anthracyclines in the treatment of multiple myeloma
Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
research Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer
The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research Salvage Chemotherapy in Follicular Non-Hodgkin's Lymphoma: Focus on Tolerability
Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.
research Innovative sequence of docetaxel–gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study
The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
research 2 SIDES OF LUPUS: CASE REPORT
Living with lupus as both a patient and doctor improved understanding and care for others.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.